Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

High numbers of activated helper T cells are associated with better clinical outcome in early stage vulvar cancer, irrespective of HPV or p53 status.

Kortekaas KE, Santegoets SJ, Abdulrahman Z, van Ham VJ, van der Tol M, Ehsan I, van Doorn HC, Bosse T, van Poelgeest MIE, van der Burg SH.

J Immunother Cancer. 2019 Sep 3;7(1):236. doi: 10.1186/s40425-019-0712-z.

2.

Correction to: Autologous tumor cell vaccination combined with systemic CpG-B and IFN-α promotes immune activation and induces clinical responses in patients with metastatic renal cell carcinoma: a phase II trial.

Koster BD, Santegoets SJAM, Harting J, Baars A, van Ham SM, Scheper RJ, Hooijberg E, de Gruijl TD, van den Eertwegh AJM.

Cancer Immunol Immunother. 2019 Jun;68(6):1037. doi: 10.1007/s00262-019-02328-6.

PMID:
30919028
3.

Autologous tumor cell vaccination combined with systemic CpG-B and IFN-α promotes immune activation and induces clinical responses in patients with metastatic renal cell carcinoma: a phase II trial.

Koster BD, Santegoets SJAM, Harting J, Baars A, van Ham SM, Scheper RJ, Hooijberg E, de Gruijl TD, van den Eertwegh AJM.

Cancer Immunol Immunother. 2019 Jun;68(6):1025-1035. doi: 10.1007/s00262-019-02320-0. Epub 2019 Mar 9. Erratum in: Cancer Immunol Immunother. 2019 Mar 27;:.

4.

Tbet-positive regulatory T cells accumulate in oropharyngeal cancers with ongoing tumor-specific type 1 T cell responses.

Santegoets SJ, Duurland CL, Jordanova ES, van Ham JJ, Ehsan I, van Egmond SL, Welters MJP, van der Burg SH.

J Immunother Cancer. 2019 Jan 18;7(1):14. doi: 10.1186/s40425-019-0497-0.

5.

Tumor microenvironment modulation enhances immunologic benefit of chemoradiotherapy.

Hanoteau A, Newton JM, Krupar R, Huang C, Liu HC, Gaspero A, Gartrell RD, Saenger YM, Hart TD, Santegoets SJ, Laoui D, Spanos C, Parikh F, Jayaraman P, Zhang B, Van der Burg SH, Van Ginderachter JA, Melief CJM, Sikora AG.

J Immunother Cancer. 2019 Jan 15;7(1):10. doi: 10.1186/s40425-018-0485-9.

6.

NKG2A Blockade Potentiates CD8 T Cell Immunity Induced by Cancer Vaccines.

van Montfoort N, Borst L, Korrer MJ, Sluijter M, Marijt KA, Santegoets SJ, van Ham VJ, Ehsan I, Charoentong P, André P, Wagtmann N, Welters MJP, Kim YJ, Piersma SJ, van der Burg SH, van Hall T.

Cell. 2018 Dec 13;175(7):1744-1755.e15. doi: 10.1016/j.cell.2018.10.028. Epub 2018 Nov 29.

PMID:
30503208
7.

The Anatomical Location Shapes the Immune Infiltrate in Tumors of Same Etiology and Affects Survival.

Santegoets SJ, van Ham VJ, Ehsan I, Charoentong P, Duurland CL, van Unen V, Höllt T, van der Velden LA, van Egmond SL, Kortekaas KE, de Vos van Steenwijk PJ, van Poelgeest MIE, Welters MJP, van der Burg SH.

Clin Cancer Res. 2019 Jan 1;25(1):240-252. doi: 10.1158/1078-0432.CCR-18-1749. Epub 2018 Sep 17.

PMID:
30224343
8.

The blood mMDSC to DC ratio is a sensitive and easy to assess independent predictive factor for epithelial ovarian cancer survival.

Santegoets SJAM, de Groot AF, Dijkgraaf EM, Simões AMC, van der Noord VE, van Ham JJ, Welters MJP, Kroep JR, van der Burg SH.

Oncoimmunology. 2018 May 31;7(8):e1465166. doi: 10.1080/2162402X.2018.1465166. eCollection 2018.

9.

EGFR signaling suppresses type 1 cytokine-induced T-cell attracting chemokine secretion in head and neck cancer.

Ma W, Concha-Benavente F, Santegoets SJAM, Welters MJP, Ehsan I, Ferris RL, van der Burg SH.

PLoS One. 2018 Sep 7;13(9):e0203402. doi: 10.1371/journal.pone.0203402. eCollection 2018.

10.

A novel allogeneic off-the-shelf dendritic cell vaccine for post-remission treatment of elderly patients with acute myeloid leukemia.

van de Loosdrecht AA, van Wetering S, Santegoets SJAM, Singh SK, Eeltink CM, den Hartog Y, Koppes M, Kaspers J, Ossenkoppele GJ, Kruisbeek AM, de Gruijl TD.

Cancer Immunol Immunother. 2018 Oct;67(10):1505-1518. doi: 10.1007/s00262-018-2198-9. Epub 2018 Jul 23.

11.

Intratumoral HPV16-Specific T Cells Constitute a Type I-Oriented Tumor Microenvironment to Improve Survival in HPV16-Driven Oropharyngeal Cancer.

Welters MJP, Ma W, Santegoets SJAM, Goedemans R, Ehsan I, Jordanova ES, van Ham VJ, van Unen V, Koning F, van Egmond SI, Charoentong P, Trajanoski Z, van der Velden LA, van der Burg SH.

Clin Cancer Res. 2018 Feb 1;24(3):634-647. doi: 10.1158/1078-0432.CCR-17-2140. Epub 2017 Oct 10.

12.

Immunological effects of everolimus in patients with metastatic renal cell cancer.

Huijts CM, Santegoets SJ, de Jong TD, Verheul HM, de Gruijl TD, van der Vliet HJ.

Int J Immunopathol Pharmacol. 2017 Dec;30(4):341-352. doi: 10.1177/0394632017734459. Epub 2017 Oct 9.

13.

Monitoring of the Immune Dysfunction in Cancer Patients.

Santegoets SJ, Welters MJ, van der Burg SH.

Vaccines (Basel). 2016 Sep 2;4(3). pii: E29. doi: 10.3390/vaccines4030029. Review.

14.

Differential effects of inhibitors of the PI3K/mTOR pathway on the expansion and functionality of regulatory T cells.

Huijts CM, Santegoets SJ, Quiles Del Rey M, de Haas RR, Verheul HM, de Gruijl TD, van der Vliet HJ.

Clin Immunol. 2016 Jul;168:47-54. doi: 10.1016/j.clim.2016.05.005. Epub 2016 May 14.

15.

Improved efficacy of mitoxantrone in patients with castration-resistant prostate cancer after vaccination with GM-CSF-transduced allogeneic prostate cancer cells.

van Dodewaard-de Jong JM, Santegoets SJ, van de Ven PM, Versluis J, Verheul HM, de Gruijl TD, Gerritsen WR, van den Eertwegh AJ.

Oncoimmunology. 2015 Dec 21;5(4):e1105431. eCollection 2016 Apr.

16.

Vaccination during myeloid cell depletion by cancer chemotherapy fosters robust T cell responses.

Welters MJ, van der Sluis TC, van Meir H, Loof NM, van Ham VJ, van Duikeren S, Santegoets SJ, Arens R, de Kam ML, Cohen AF, van Poelgeest MI, Kenter GG, Kroep JR, Burggraaf J, Melief CJ, van der Burg SH.

Sci Transl Med. 2016 Apr 13;8(334):334ra52. doi: 10.1126/scitranslmed.aad8307.

PMID:
27075626
17.

Local delivery of CpG-B and GM-CSF induces concerted activation of effector and regulatory T cells in the human melanoma sentinel lymph node.

van den Hout MF, Sluijter BJ, Santegoets SJ, van Leeuwen PA, van den Tol MP, van den Eertwegh AJ, Scheper RJ, de Gruijl TD.

Cancer Immunol Immunother. 2016 Apr;65(4):405-15. doi: 10.1007/s00262-016-1811-z. Epub 2016 Mar 2.

18.

A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer.

Dijkgraaf EM, Santegoets SJ, Reyners AK, Goedemans R, Nijman HW, van Poelgeest MI, van Erkel AR, Smit VT, Daemen TA, van der Hoeven JJ, Melief CJ, Welters MJ, Kroep JR, van der Burg SH.

Oncotarget. 2015 Oct 13;6(31):32228-43. doi: 10.18632/oncotarget.4772.

19.

A phase I trial combining carboplatin/doxorubicin with tocilizumab, an anti-IL-6R monoclonal antibody, and interferon-α2b in patients with recurrent epithelial ovarian cancer.

Dijkgraaf EM, Santegoets SJ, Reyners AK, Goedemans R, Wouters MC, Kenter GG, van Erkel AR, van Poelgeest MI, Nijman HW, van der Hoeven JJ, Welters MJ, van der Burg SH, Kroep JR.

Ann Oncol. 2015 Oct;26(10):2141-9. doi: 10.1093/annonc/mdv309. Epub 2015 Jul 27.

PMID:
26216383
20.

Monitoring regulatory T cells in clinical samples: consensus on an essential marker set and gating strategy for regulatory T cell analysis by flow cytometry.

Santegoets SJ, Dijkgraaf EM, Battaglia A, Beckhove P, Britten CM, Gallimore A, Godkin A, Gouttefangeas C, de Gruijl TD, Koenen HJ, Scheffold A, Shevach EM, Staats J, Taskén K, Whiteside TL, Kroep JR, Welters MJ, van der Burg SH.

Cancer Immunol Immunother. 2015 Oct;64(10):1271-86. doi: 10.1007/s00262-015-1729-x. Epub 2015 Jun 28.

21.

Development of thyroglobulin antibodies after GVAX immunotherapy is associated with prolonged survival.

De Remigis A, de Gruijl TD, Uram JN, Tzou SC, Iwama S, Talor MV, Armstrong TD, Santegoets SJ, Slovin SF, Zheng L, Laheru DA, Jaffee EM, Gerritsen WR, van den Eertwegh AJ, Le DT, Caturegli P.

Int J Cancer. 2015 Jan 1;136(1):127-37. doi: 10.1002/ijc.28973. Epub 2014 May 28.

22.

The Thirteenth International Conference on Progress in Vaccination Against Cancer (PIVAC-13), October 2-4, 2013, Amsterdam, The Netherlands: the current standing of anti-tumor immunotherapeutic approaches.

Melief SM, Visconti VV, Doorduijn EM, Santegoets SJ.

Cancer Immunol Immunother. 2014 Oct;63(10):1105-12. doi: 10.1007/s00262-014-1532-0. Epub 2014 Mar 12. No abstract available.

PMID:
24619351
23.

Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumab.

Santegoets SJ, Stam AG, Lougheed SM, Gall H, Jooss K, Sacks N, Hege K, Lowy I, Scheper RJ, Gerritsen WR, van den Eertwegh AJ, de Gruijl TD.

J Immunother Cancer. 2014 Sep 16;2:31. doi: 10.1186/s40425-014-0031-3. eCollection 2014.

24.

IL-21 in cancer immunotherapy: At the right place at the right time.

Santegoets SJ, Turksma AW, Powell DJ Jr, Hooijberg E, de Gruijl TD.

Oncoimmunology. 2013 Jun 1;2(6):e24522. Epub 2013 Apr 16.

25.

IL-10 conditioning of human skin affects the distribution of migratory dendritic cell subsets and functional T cell differentiation.

Lindenberg JJ, Oosterhoff D, Sombroek CC, Lougheed SM, Hooijberg E, Stam AG, Santegoets SJ, Tijssen HJ, Buter J, Pinedo HM, van den Eertwegh AJ, Scheper RJ, Koenen HJ, van de Ven R, de Gruijl TD.

PLoS One. 2013 Jul 18;8(7):e70237. doi: 10.1371/journal.pone.0070237. Print 2013.

26.

Exploring dendritic cell based vaccines targeting survivin for the treatment of head and neck cancer patients.

Turksma AW, Bontkes HJ, Ruizendaal JJ, Scholten KB, Akershoek J, Rampersad S, Moesbergen LM, Cillessen SA, Santegoets SJ, de Gruijl TD, Leemans CR, Meijer CJ, Hooijberg E.

J Transl Med. 2013 Jun 20;11:152. doi: 10.1186/1479-5876-11-152.

27.

Priming of PRAME- and WT1-specific CD8+ T cells in healthy donors but not in AML patients in complete remission: Implications for immunotherapy.

van den Ancker W, Ruben JM, Westers TM, Wulandari D, Bontkes HJ, Hooijberg E, Stam AG, Santegoets SJ, Ossenkoppele GJ, de Gruijl T, van de Loosdrecht A.

Oncoimmunology. 2013 Apr 1;2(4):e23971.

28.

Functional characterization of a STAT3-dependent dendritic cell-derived CD14+ cell population arising upon IL-10-driven maturation.

Lindenberg JJ, van de Ven R, Lougheed SM, Zomer A, Santegoets SJ, Griffioen AW, Hooijberg E, van den Eertwegh AJ, Thijssen VL, Scheper RJ, Oosterhoff D, de Gruijl TD.

Oncoimmunology. 2013 Apr 1;2(4):e23837.

29.

IL-21 promotes the expansion of CD27+ CD28+ tumor infiltrating lymphocytes with high cytotoxic potential and low collateral expansion of regulatory T cells.

Santegoets SJ, Turksma AW, Suhoski MM, Stam AG, Albelda SM, Hooijberg E, Scheper RJ, van den Eertwegh AJ, Gerritsen WR, Powell DJ Jr, June CH, de Gruijl TD.

J Transl Med. 2013 Feb 12;11:37. doi: 10.1186/1479-5876-11-37.

30.

Increased cytotoxic capacity of tumor antigen specific human T cells after in vitro stimulation with IL21 producing dendritic cells.

Turksma AW, Bontkes HJ, Ruizendaal JJ, van den Heuvel H, Scholten KB, Santegoets SJ, de Gruijl TD, Meijer CJ, Hooijberg E.

Hum Immunol. 2013 May;74(5):506-13. doi: 10.1016/j.humimm.2013.01.014. Epub 2013 Jan 29.

PMID:
23376456
31.

T cell profiling reveals high CD4+CTLA-4 + T cell frequency as dominant predictor for survival after prostate GVAX/ipilimumab treatment.

Santegoets SJ, Stam AG, Lougheed SM, Gall H, Scholten PE, Reijm M, Jooss K, Sacks N, Hege K, Lowy I, Cuillerot JM, von Blomberg BM, Scheper RJ, van den Eertwegh AJ, Gerritsen WR, de Gruijl TD.

Cancer Immunol Immunother. 2013 Feb;62(2):245-56. doi: 10.1007/s00262-012-1330-5. Epub 2012 Aug 10.

PMID:
22878899
32.

Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.

van den Eertwegh AJ, Versluis J, van den Berg HP, Santegoets SJ, van Moorselaar RJ, van der Sluis TM, Gall HE, Harding TC, Jooss K, Lowy I, Pinedo HM, Scheper RJ, Stam AG, von Blomberg BM, de Gruijl TD, Hege K, Sacks N, Gerritsen WR.

Lancet Oncol. 2012 May;13(5):509-17. doi: 10.1016/S1470-2045(12)70007-4. Epub 2012 Feb 10.

PMID:
22326922
33.

An α-galactosylceramide nose job shapes up iNKT cells.

de Bruin RC, Schneiders FL, Santegoets SJ, Verheul HM, de Gruijl TD, van der Vliet HJ.

Immunotherapy. 2012 Jan;4(1):20-1. No abstract available.

PMID:
22263254
34.

Bulldozing β-linked glycolipids for recognition by invariant NKT cells.

de Bruin RC, Schneiders FL, Santegoets SJ, Verheul HM, de Gruijl TD, van der Vliet HJ.

Immunotherapy. 2012 Jan;4(1):20. No abstract available.

PMID:
22263253
35.

Gram-positive bacteria: a major microbial ‘turn-on’ for invariant NKT cells.

de Bruin RC, Schneiders FL, Santegoets SJ, Verheul HM, de Gruijl TD, van der Vliet HJ.

Immunotherapy. 2012 Jan;4(1):19. doi: 10.2217/imt.11.152. No abstract available.

PMID:
22149997
36.

Phase I-II study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell cancer.

Huijts CM, Santegoets SJ, van den Eertwegh AJ, Pijpers LS, Haanen JB, de Gruijl TD, Verheul HM, van der Vliet HJ.

BMC Cancer. 2011 Nov 30;11:505. doi: 10.1186/1471-2407-11-505.

37.

Activated iNKT cells promote Vγ9Vδ2-T cell anti-tumor effector functions through the production of TNF-α.

Schneiders FL, de Bruin RC, Santegoets SJ, Bonneville M, Scotet E, Scheper RJ, Verheul HM, de Gruijl TD, van der Vliet HJ.

Clin Immunol. 2012 Feb;142(2):194-200. doi: 10.1016/j.clim.2011.10.006. Epub 2011 Nov 4.

PMID:
22122798
38.

Research resource: transcriptome profiling of genes regulated by RXR and its permissive and nonpermissive partners in differentiating monocyte-derived dendritic cells.

Széles L, Póliska S, Nagy G, Szatmari I, Szanto A, Pap A, Lindstedt M, Santegoets SJ, Rühl R, Dezsö B, Nagy L.

Mol Endocrinol. 2010 Nov;24(11):2218-31. doi: 10.1210/me.2010-0215. Epub 2010 Sep 22.

39.

4-1BB-mediated expansion affords superior detection of in vivo primed effector memory CD8+ T cells from melanoma sentinel lymph nodes.

Sluijter BJ, van den Hout MF, Stam AG, Lougheed SM, Suhoski MM, van den Eertwegh AJ, van den Tol MP, van Leeuwen PA, Meijer S, Scheper RJ, June CH, de Gruijl TD, Santegoets SJ.

Clin Immunol. 2010 Nov;137(2):221-33. doi: 10.1016/j.clim.2010.07.009. Epub 2010 Aug 13.

PMID:
20708974
40.

Selective transduction of dendritic cells in human lymph nodes and superior induction of high-avidity melanoma-reactive cytotoxic T cells by a CD40-targeted adenovirus.

Hangalapura BN, Oosterhoff D, Aggarwal S, Wijnands PG, van de Ven R, Santegoets SJ, van den Tol MP, Hooijberg E, Pereboev A, van den Eertwegh AJ, Curiel DT, Scheper RJ, de Gruijl TD.

J Immunother. 2010 Sep;33(7):706-15. doi: 10.1097/CJI.0b013e3181eccbd4.

PMID:
20664356
41.

Impact of varicella-zoster virus on dendritic cell subsets in human skin during natural infection.

Huch JH, Cunningham AL, Arvin AM, Nasr N, Santegoets SJ, Slobedman E, Slobedman B, Abendroth A.

J Virol. 2010 Apr;84(8):4060-72. doi: 10.1128/JVI.01450-09. Epub 2010 Feb 3.

42.

Mutz-3-derived Langerhans cells are a model to study HIV-1 transmission and potential inhibitors.

de Jong MA, de Witte L, Santegoets SJ, Fluitsma D, Taylor ME, de Gruijl TD, Geijtenbeek TB.

J Leukoc Biol. 2010 Apr;87(4):637-43. doi: 10.1189/jlb.0809577. Epub 2009 Dec 30.

PMID:
20042470
43.

CXCL12 is essential for migration of activated Langerhans cells from epidermis to dermis.

Ouwehand K, Santegoets SJ, Bruynzeel DP, Scheper RJ, de Gruijl TD, Gibbs S.

Eur J Immunol. 2008 Nov;38(11):3050-9. doi: 10.1002/eji.200838384.

44.

Human dendritic cell line models for DC differentiation and clinical DC vaccination studies.

Santegoets SJ, van den Eertwegh AJ, van de Loosdrecht AA, Scheper RJ, de Gruijl TD.

J Leukoc Biol. 2008 Dec;84(6):1364-73. doi: 10.1189/jlb.0208092. Epub 2008 Jul 29. Review.

PMID:
18664532
45.

Local administration of PF-3512676 CpG-B instigates tumor-specific CD8+ T-cell reactivity in melanoma patients.

Molenkamp BG, Sluijter BJ, van Leeuwen PA, Santegoets SJ, Meijer S, Wijnands PG, Haanen JB, van den Eertwegh AJ, Scheper RJ, de Gruijl TD.

Clin Cancer Res. 2008 Jul 15;14(14):4532-42. doi: 10.1158/1078-0432.CCR-07-4711.

46.

Transcriptional profiling of human skin-resident Langerhans cells and CD1a+ dermal dendritic cells: differential activation states suggest distinct functions.

Santegoets SJ, Gibbs S, Kroeze K, van de Ven R, Scheper RJ, Borrebaeck CA, de Gruijl TD, Lindstedt M.

J Leukoc Biol. 2008 Jul;84(1):143-51. doi: 10.1189/jlb.1107750. Epub 2008 Apr 24.

PMID:
18436579
47.

Inducing antitumor T cell immunity: comparative functional analysis of interstitial versus Langerhans dendritic cells in a human cell line model.

Santegoets SJ, Bontkes HJ, Stam AG, Bhoelan F, Ruizendaal JJ, van den Eertwegh AJ, Hooijberg E, Scheper RJ, de Gruijl TD.

J Immunol. 2008 Apr 1;180(7):4540-9.

48.

Identification and characterization of ErbB-3-binding protein-1 as a target for immunotherapy.

Santegoets SJ, Schreurs MW, Reurs AW, Lindenberg JJ, Kueter EW, van den Eertwegh AJ, Hooijberg E, Brandwijk RJ, Hufton SE, Hoogenboom HR, Scheper RJ, Somers VA, de Gruijl TD.

J Immunol. 2007 Aug 1;179(3):2005-12.

49.

A CD34(+) human cell line model of myeloid dendritic cell differentiation: evidence for a CD14(+)CD11b(+) Langerhans cell precursor.

Santegoets SJ, Masterson AJ, van der Sluis PC, Lougheed SM, Fluitsma DM, van den Eertwegh AJ, Pinedo HM, Scheper RJ, de Gruijl TD.

J Leukoc Biol. 2006 Dec;80(6):1337-44. Epub 2006 Sep 7.

PMID:
16959899
50.

Constitutively active STAT5b induces cytokine-independent growth of the acute myeloid leukemia-derived MUTZ-3 cell line and accelerates its differentiation into mature dendritic cells.

Bontkes HJ, Ruizendaal JJ, Kramer D, Santegoets SJ, Scheper RJ, de Gruijl TD, Meijer CJ, Hooijberg E.

J Immunother. 2006 Mar-Apr;29(2):188-200.

PMID:
16531819

Supplemental Content

Loading ...
Support Center